Pediatric Acute Respiratory Distress Management

Pediatric acute respiratory distress syndrome (pARDS) represents a severe form of respiratory failure characterised by diffuse pulmonary inflammation, hypoxaemia and reduced lung compliance. Management hinges on early recognition of precipitating factors such as pneumonia, sepsis or aspiration, followed by supportive strategies tailored to the paediatric lung. Protective mechanical ventilation with reduced tidal volumes and judicious positive end-expiratory pressure minimises ventilator-induced lung injury. Adjunctive measures—such as prone positioning, neuromuscular blockade and conservative fluid management—can improve oxygenation and reduce barotrauma. In selected cases, high-frequency oscillatory ventilation and inhaled pulmonary vasodilators offer targeted support. Emerging approaches include personalised immunomodulation and biologics guided by molecular profiling. Optimising ventilator-free days, reducing complications and standardising core outcome measures remain central to advancing clinical trials and improving global outcomes for children with pARDS.

Research from Nature Portfolio

Single-cell transcriptomic profiling of tracheal aspirates in infants with pARDS has revealed distinct inflammatory programmes linked to disease severity. Moderate to severe cases exhibit diminished interferon-stimulated gene expression, altered macrophage repair programmes and accumulation of aged neutrophils, whereas a novel innate immune marker, folate receptor 3, correlates with worst outcomes. These findings underscore the heterogeneity of pARDS and point to cell-type–specific pathways that may guide precision therapies aimed at restoring balanced antiviral and reparative responses.

Pediatric Acute Respiratory Distress Management publication trend

The graph below shows the total number of articles in pediatric acute respiratory distress management across all publications each year (not limited to Nature Index journals).

Technical terms

Pediatric ARDS (pARDS): Acute respiratory distress syndrome occurring in infants and children, defined by hypoxaemia and diffuse alveolar injury.

Single-cell transcriptomics: High-resolution profiling of gene expression in individual cells to uncover cellular heterogeneity.

Folate receptor 3 (FOLR3): An innate immune protein enriched in severe pARDS, indicative of dysregulated inflammation.

Alveolar dead space fraction (AVDSf): A measure of ventilated but unperfused lung units, calculated from PaCO₂ and end-tidal CO₂.

High-frequency oscillatory ventilation (HFOV): A mechanical ventilation mode delivering very small tidal volumes at high frequency to reduce lung injury.

Inhaled nitric oxide (iNO): A selective pulmonary vasodilator administered via the airway to improve oxygenation in heterogeneous lung injury.

References

1. Single cell transcriptomics identifies distinct profiles in pediatric acute respiratory distress syndrome. Nature Communications (2023).
2. Modes of administration of nitric oxide devices and ventilators flow-by impact the delivery of pre-determined concentrations. Annals of Intensive Care (2024).
3. The end-tidal alveolar dead space fraction for risk stratification during the first week of invasive mechanical ventilation: an observational cohort study. Critical Care (2023).
4. A shared protocol for porcine surfactant use in pediatric acute respiratory distress syndrome: a feasibility study. BMC Pediatrics (2019).